|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helicobacter pylori infection and endocrine disorders:Is there a link?显示文摘Helicobacter pylori(H pylori) infection is a leading world-wide infectious disease as it affects more than half of the world population and causes chronic gastritis,peptic ulcer disease and gastric malignancies.The infection elicits a chronic cellular inflammatory response in the gastric mucosa.However,the effects of this local inflammation may not be confi ned solely to the digestive tract but may spread to involve extraintestinal tissues and/or organs.Indeed,H pylori infection has been epidemiologically linked to extra-digestive conditions and diseases.In this context,it has been speculated that H pylori infection may be responsible for various endocrine disorders,such as autoimmune thyroid diseases,diabetes mellitus,dyslipidemia,obesity,osteoporosis and primary hyperparathyroidism.This is a review of the relationship between H pylori infection and these endocrine disorders. | Konstantinos X Papamichael Garyphallia Papaioannou Helen Karga Anastasios Roussos Gerassimos J Mantzaris | 2009 | World Journal of Gastroenterology2009，15，22： | 42 |
| 2 | Helicobacter pylori infection and inflammatory bowel disease: Is there a link?显示文摘Helicobacter pylori(H.pylori)infection is one of the most widely spread infectious diseases in humans.It can cause chronic gastritis,peptic ulcer disease and gastric malignancies and has been associated with extra-gastric disorders.H.pylori elicit a chronic systemic inflammatory response which,under certain conditions,may trigger autoimmune reactions and may be implicated in the pathogenesis of autoimmune diseases.Although the pathogenesis of inflammatory bowel disease(IBD)is unknown,it is thought to result from complex interactions between environmental factors and microbiota in the gut of individuals who are genetically susceptible.Several bacterial and viral agents have been implicated in the aetiology of IBD.In theory,H.pylori infection could be involved in the pathogenesis of IBD by inducing alterations in gastric and/or intestinal permeability or by causing immunological derangements resulting in absorption of antigenic material and autoimmunity via various immunological pathways.Similar mechanisms may also be responsible for the co-existence of IBD with other autoimmune diseases and/or extra-intestinal manifestations.However,the epidemiological data fail to support this association.Infact,various studies indicate that the prevalence of H.pylori infection is low in patients with IBD,suggesting a protective role for this infection in the development of IBD.In this report,we aim to shed light on proposed mechanisms and confounding factors underlying the potential link between H.pylori infection and IBD. | Konstantinos Papamichael Panagiotis Konstantopoulos Gerassimos J Mantzaris | 2014 | World Journal of Gastroenterology2014，20，21： | 33 |
| 3 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 4 | Osteoporosis in primary biliary cholangitis显示文摘Primary biliary cholangitis(PBC) is an autoimmune cholestatic liver disease with multiple debilitating complications. Osteoporosis is a common complication of PBC resulting in frequent fractures and leading to significant morbidity in this population, yet evidence for effective therapy is lacking. We sought to summarize our current understanding of the pathophysiology of osteoporosis in PBC, as well as current and emerging therapies in order to guide future research directions. A complete search with a comprehensive literature review was performed with studies from Pub Med, EMBASE, Web of Science, Cochrane database, and the Countway Library. Osteoporosis in PBC is driven primarily by decreased bone formation, which differs from the increased bone resorption seen in postmenopausal osteoporosis. Despite this fundamental difference, current treatment recommendations are based primarily on experience with postmenopausal osteoporosis. Trials specific to PBC-related osteoporosis are small and have not consistently demonstrated a benefit in this population. As it stands, prevention of osteoporosis in PBC relies on the mitigation of risk factors such as smoking and alcohol use, as well as encouraging a healthy diet and weight-bearing exercise. The primary medical intervention for the treatment of osteoporosis in PBC remains bisphosphonates though a benefit in terms of fracture reduction has never been shown. This review outlines what is known regarding the pathogenesis of bone disease in PBC and summarizes current and emerging therapies. | Christopher J Danford Hirsh D Trivedi Konstantinos Papamichael Elliot B Tapper Alan Bonder | 2018 | World Journal of Gastroenterology2018，24，31： | 13 |
| 5 | Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis显示文摘 | Wendy De Roock Bart Claes David Bernasconi Jef De Schutter Bart Biesmans George Fountzilas Konstantine T Kalogeras Vassiliki Kotoula Demetris Papamichael Pierre Laurent-Puig Frédérique Penault-Llorca Philippe Rougier Bruno Vincenzi Daniele Santini Giusepp | 2010 | Lancet Oncology2010，，8： | 6 |
| 6 | Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy显示文摘Perianal fistulas can occur to up to one-third of patients with Crohn's disease(CD) leading to significant disabling disease and morbidity. Fistulising perianal CD treatment often necessitates a combined pharmacological and surgical approach. Anti-tumor necrosis factor(anti-TNF) therapy, particularly infliximab, has been shown to be very effective for both perianal and internal fistulising CD. Nevertheless, current data suggest that sustained remission and long-term complete fistula healing can be achieved in only 30% to 50% of patients. Moreover, these percentages refer mostly to clinical rather than deep remission, defined as endoscopic and radiologic remission, which is quickly emerging as the preferred goal of therapy. Unfortunately, the therapeutic options for perianal fistulising CD are still limited. As such, it would be of great value to be able to predict, and more importantly, prevent treatment failure in these patients by early and continued optimization of antiTNF therapy. Similar to ulcerative colitis and luminal CD, recent data demonstrate that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD. This suggests that therapeutic drug monitoring and a treatto-trough therapeutic approach may emerge as the new standard of care for optimizing anti-TNF therapy in patients with perianal fistulising CD. | konstantinos papamichael adam s cheifetz | 2017 | World Journal of Gastroenterology2017，23，34： | 2 |
| 7 | Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease显示文摘Anti-tumour necrosis factor α(anti-TNFα) therapy is an established treatment in inflammatory bowel disease.However, this treatment is associated with high costs and the possibility of severe adverse events representing a true challenge for patients, clinicians and health care systems.Consequently, a crucial question is raised namely if therapy can be stopped once remission is achieved and if so, how and in whom.Additionally, in a real-life clinical setting, discontinuation may also be considered for other reasons such as the patient's preference, pregnancy, social reasons as moving to countries or continents with less access, or different local policy or reimbursement.In contrast to initiation of anti-TNFα therapy guidelines regarding stopping of this treatment are missing.As a result, the decision of discontinuation is still a challenging aspect in the use of anti-TNFα therapy.Currently this is typically based on an estimated, case-by-case, benefit-risk ratio.This editorial is intended to provide an overview of recent data on this topic and shed light on the proposed drug withdrawal strategies. | Konstantinos Papamichael Severine Vermeire | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 8 | Time Rate of Blood Pressure Variation Is Associated With Increased Common Carotid Artery Intima-Media Thickness显示文摘 | Nikos A. Zakopoulos Georgios Tsivgoulis Gerassimos Barlas Christos Papamichael Konstantinos Spengos Efstathios Manios Ignatios Ikonomidis Vassilios Kotsis Ioanna Spiliopoulou Konstantinos Vemmos Myron Mavrikakis Spyridon D. Moulopoulos | 2005 | Hypertension2005，，4： | 2 |
| 9 | Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease 显示文摘 | Lekakis JP Protogerou A Papamichael C | 2005 | Cardiovasc Drugs Ther2005，19，4： | 1 |
| 10 | Acute effects of caffeine on arterial stiffness, wave reflections, and central aortic pressures显示文摘 | Theodoros G. Papaioannou Kalliopi Karatzi Emmanouil Karatzis Christos Papamichael John P. Lekakis | 2005 | American Journal of Hypertension2005，，1： | 1 |
| 11 | Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis显示文摘 | Lekakis JP Papamichael CM Cimponeriu AT | 2000 | Am J Cardiol2000，85，8： | 1 |
| 12 | Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with cor- onary artery disease显示文摘 | Papamichael CM Lekakis JP Stamatelopoulos KS | 2000 | Am J Cardiol2000，86，6： | 1 |
| 13 | Ankle- brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patientswith coronary artery disease 显示文摘 | Papamichael CM Lekakis JP Stamatelopoulos KS | 2000 | AmJCardiol2000，86，6： | 1 |
| 14 | Atheresclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis 显示文摘 | Lekakis JP Papamichael CM Cimponeriu AT | 2000 | Am J Cardio]2000，85，： | 1 |
| 15 | Flow-mediated, endotheli- urn-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin ( TSH ) values 显示文摘 | Lekakis J Papamichael C Alevizaki M | 1997 | Thyroid1997，7，3： | 1 |
| 16 | 进食频率预测新发高血压及血压、动脉硬化和脉搏波反射进展率显示文摘普遍认为每天至少吃3餐,但现代生活方式正逐渐打破既往进食习惯。已发现每日进食频率可能影响多种心血管代谢风险因素,但尚未深入研究其临床价值。研究显示,与进食次数较少者相比,进食次数较多者通常血脂状况更好,胰岛素抵抗及代谢综合征发病风险更低。进食频率增加使空腹时间减少,平均血糖浓度及胰岛素分泌量降低。胰岛素浓度降低使羟甲基戊二酸单酰辅酶A还原酶活性降低,从而减少肝脏胆固醇合成。 | Karatzi K Georgiopoulos G Yannakoulia M Efthimiou E Voidonikola P Mitrakou A Manios E Alevizaki M Papamichael C Stamatelopoulos K 曲浥晨 | 2016 | 中华高血压杂志2016，24，5： | 1 |
| 17 | A Clinical Trial of Mediterranean Diet Enriched with Fatty Fish in Pediatric Asthma: Study Protocol显示文摘 | Maria Michelle Papamichael Chaffs Katsardis Dimitffs Tsoukalas Bircan Erbas Catherine Itsiopoulos | 2018 | Journal of Pharmacy and Pharmacology2018，6，3： | 1 |
| 18 | Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease显示文摘 | Papamichael CM Lekakis JP Stamatelopoulos KS | 2000 | Am J Cardiol2000，86，： | 1 |
| 19 | Pulse pressure in normotensives: a make of cardiovarscular disease 显示文摘 | Zakopoulos NA Lekakis JP Papamichael CM | 2011 | Am J Hypertens2011，14，3： | 1 |
| 20 | DNA aptamers against the MUC1 tumour marker:design of aptamer-antibody sandwich ELISA for the early diagn osis of epithelial tumours显示文摘 | Ferreira CS Papamichael K Guilbault G | 2008 | Anal Bioanal Chem2008，390，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员